Blocking a cellular inflammation process could result in effective therapy for pancreatic cancer

Scientists at The Wistar Institute and clinical researchers from ChristianaCare's Helen F. Graham Cancer Center & Research Institute have discovered a vulnerability in pancreatic cancer that could be targeted as a potential therapy. In a new study, published in the Proceedings of the National Academy of Sciences, they show how defective mitochondria within cells spark a process that triggers inflammation. They also show how cancer cells become so dependent on this inflammation to grow that without it, they die.